Synucleinopathy Neurons is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
This page provides comprehensive information about the cell type. See the content below for detailed information.
Synucleinopathy neurons are neuronal populations that accumulate alpha-synuclein (α-syn) inclusions, forming Lewy bodies, Lewy neurites, or glial cytoplasmic inclusions. These neurons are central to Parkinson's disease, Dementia with Lewy Bodies, and multiple system atrophy.
- α-syn monomer: Normal synaptic protein
- α-syn oligomers: Toxic intermediate species
- α-syn fibrils: Major component of inclusions
- pS129-α-syn: Phosphorylated at Serine 129 (pathological)
- Lewy bodies: Intracellular, spherical inclusions
- Lewy neurites: Axonal, thread-like inclusions
- GCI (Glial Cytoplasmic Inclusions): Oligodendroglial (MSA)
-
Substantia nigra pars compacta dopaminergic neurons
- Most affected in classic PD
- 50-70% loss at clinical presentation
- Lewy bodies in remaining neurons
-
Locus coeruleus noradrenergic neurons
- Early involvement
- Contributes to non-motor symptoms
-
Nucleus basalis of Meynert cholinergic neurons
- Later involvement
- Contributes to cognitive decline
- Oligodendrocytes
- GCIs are hallmark
- Less neuronal loss than PD
- Misfolding: Normal α-syn → pathological conformation
- Oligomerization: Toxic oligomers form
- Fibrillization: Formation of insoluble fibrils
- Propagation: Spread via prion-like mechanism
- Synaptic dysfunction: Loss of SNARE complexes
- Mitochondrial impairment: Complex I inhibition
- ER stress: Disrupted protein folding
- Lysosomal dysfunction: Autophagy impairment
- Neuroinflammation: Microglial activation
- Trans-synaptic spread: Neuron to neuron
- Exosome release: Extracellular vesicles
- Tunneling nanotubes: Direct cell contact
- Immunotherapies: Active and passive vaccination
- Small molecule inhibitors: Anle138b, CLR01
- Gene therapy: ASO targeting SNCA
- BBB-penetrant compounds: Synuclein modulators
- Neurotrophic factors: GDNF, CDNF
- Antioxidants: CoQ10, glutathione
- Autophagy enhancers: Rapamycin
- pS129-α-syn in CSF
- Skin biopsy for phosphorylated α-syn
- DaTscan imaging
The study of Synucleinopathy Neurons has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
- Spillantini, M.G., et al. (1997). Alpha-synuclein in Lewy bodies. Nature, 388(6645), 839-840.
- Winner, B., et al. (2011). Role of alpha-synuclein in Parkinson's disease. Nature Reviews Neuroscience, 12(9), 501-512.
- Luk, K.C., et al. (2012). Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice. Science, 338(6109), 949-953.
- Braak, H., et al. (2003). Staging of brain pathology related to sporadic Parkinson's disease. Neurobiology of Aging, 24(2), 197-211.
- Volpicelli-Daley, L.A., et al. (2011). Exogenous alpha-synuclein fibrils induce Lewy body pathology. Neuron, 70(4), 713-727.